820 Shares in Stryker Co. (NYSE:SYK) Bought by Rothschild Capital Partners LLC

Rothschild Capital Partners LLC acquired a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 820 shares of the medical technology company's stock, valued at approximately $295,000.

Other large investors also recently modified their holdings of the company. Chicago Capital LLC grew its holdings in Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after purchasing an additional 5,841 shares during the period. Zhang Financial LLC grew its holdings in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after purchasing an additional 40,784 shares during the period. Appleton Partners Inc. MA grew its holdings in Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after purchasing an additional 1,400 shares during the period. Metis Global Partners LLC grew its holdings in Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after purchasing an additional 1,561 shares during the period. Finally, US Bancorp DE grew its holdings in Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after purchasing an additional 976 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Performance

NYSE SYK traded down $0.80 on Wednesday, hitting $370.12. 864,251 shares of the stock traded hands, compared to its average volume of 1,577,444. The business's fifty day moving average is $367.06 and its two-hundred day moving average is $373.49. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market capitalization of $141.27 billion, a price-to-earnings ratio of 47.70, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business earned $3.46 earnings per share. As a group, equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.